Peptide Regulation: US, EU, UK, Australia Compared

Peptide Regulation

4 major regulators

The FDA, EMA, MHRA, and TGA each apply different rules to peptide drugs, from approval pathways to compounding to personal importation.

Nordell et al., Clin Pharmacokinet, 2026

Nordell et al., Clin Pharmacokinet, 2026

View as image

A peptide drug approved in the United States may not be legal to prescribe in Australia. A compounded peptide sold over the counter in one country may be a controlled substance in another. These regulatory differences matter because peptide research is global, peptide commerce is global, and patients increasingly source peptides across borders. The FDA, EMA, MHRA, and TGA each classify, approve, and monitor peptide drugs through different frameworks, with meaningful consequences for access, quality, and safety. This article compares how each jurisdiction handles peptide drug approval, compounding, personal importation, and research use. For the broader context on peptide importation specifically, see our pillar article on peptide importation laws.

United States: FDA

The FDA regulates peptide drugs through its Center for Drug Evaluation and Research (CDER). Peptides of 40 or fewer amino acids are classified as small molecules and follow standard New Drug Application (NDA) or Abbreviated New Drug Application (ANDA) pathways. Larger peptides and proteins follow the Biologics License Application (BLA) pathway through the Center for Biologics Evaluation and Research (CBER), though the Biologics Price Competition and Innovation Act (BPCIA) has shifted some peptide products between these categories.

As of 2025, over 130 FDA-approved peptide products have been designated as reference listed drugs. Nordell et al. (2026) reviewed the systemic pharmacokinetic principles of therapeutic peptides, noting that the FDA's regulatory framework requires detailed characterization of absorption, distribution, metabolism, and excretion (ADME) properties that differ fundamentally from small molecules due to peptides' susceptibility to enzymatic degradation and limited oral bioavailability.^[1]

FDA compounding rules

Peptide compounding in the US operates under two frameworks. Section 503A of the Federal Food, Drug, and Cosmetic Act allows traditional compounding pharmacies to prepare patient-specific prescriptions. Section 503B allows outsourcing facilities to produce compounded drugs in larger batches without individual prescriptions but requires registration with the FDA and adherence to Current Good Manufacturing Practice (cGMP) standards.

In January 2025, the FDA revised its interim policy on bulk drug substances used by compounding pharmacies, significantly restricting which peptides can be compounded. In September 2025, the FDA sent more than 50 warning letters to companies compounding or manufacturing GLP-1 receptor agonists (semaglutide and tirzepatide), citing quality and safety concerns.

DiStefano et al. (2025) documented the direct-to-consumer compounded GLP-1 market in Colorado, finding that compounded semaglutide was widely available through telehealth platforms with minimal medical oversight.^[2] Hendrix et al. (2025) found that documentation of compounded GLP-1 agonist use in primary care medical records was inconsistent, creating gaps in safety monitoring.^[3]

Hach et al. (2024) compared the quality of follow-on (compounded) GLP-1 polypeptide drugs to branded formulations. They found measurable differences in purity, impurity profiles, and stability characteristics, concluding that manufacturing process and compounding methods directly impact the quality of peptide drug products.^[4]

Liu et al. (2025) provided a clinical overview of compounded semaglutide for healthcare providers, noting that compounded versions may use semaglutide sodium salt (not the base form used in Wegovy/Ozempic), which has different pharmacokinetic properties and is not bioequivalent to the branded product.^[5]

European Union: EMA

The European Medicines Agency (EMA) regulates peptide drugs through centralized, decentralized, and national authorization procedures. The centralized procedure (mandatory for certain drug categories, optional for others) results in a single marketing authorization valid across all EU member states.

In 2024, the EMA released draft quality guidelines specifically for synthetic peptide drug substances and products. These guidelines establish manufacturing standards, impurity limits, and analytical methods that peptide manufacturers must meet for EU market authorization. The guidelines address peptide-specific challenges including racemization, aggregation, oxidation, and sequence-related impurities that do not apply to traditional small-molecule drugs.

The EMA's Committee for Medicinal Products for Human Use (CHMP) evaluates peptide drugs using the same benefit-risk framework applied to all pharmaceuticals, but with additional attention to immunogenicity (the potential for peptides to trigger immune responses) and product consistency across manufacturing batches.

EU compounding differences

Compounding in the EU varies by member state. Unlike the US, there is no unified EU-wide compounding framework. Germany allows "Rezepturarzneimittel" (prescription compounding) under the Arzneimittelgesetz. France restricts compounding to hospital pharmacies for most preparations. The Netherlands has a more permissive framework. This patchwork means that a compounded peptide legally available in one EU country may be unavailable in a neighboring country.

For a detailed examination of EMA peptide regulation, see our article on how the EMA regulates peptide drugs.

United Kingdom: MHRA

Following Brexit, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) operates independently from the EMA. Peptide drugs previously approved through the EMA's centralized procedure retained their UK marketing authorizations through a "grandfathering" provision, but new peptide drugs must now be approved separately by the MHRA.

The MHRA introduced the Innovative Licensing and Access Pathway (ILAP) in 2021, specifically designed to accelerate access to innovative medicines. ILAP allows pharmaceutical companies to engage with the MHRA early in development, receive a target development profile, and access rolling review of data as it becomes available. This is particularly relevant for novel peptide drugs in competitive therapeutic areas like obesity and diabetes, where speed to market matters.

The UK also uses the International Recognition Procedure, which allows the MHRA to leverage approval decisions from trusted international regulators (including the FDA, EMA, TGA, Health Canada, and others) to expedite its own review. For peptide drugs already approved by the FDA or EMA, this can reduce UK approval timelines from years to months.

UK prescribing and access

In the UK, peptide drugs are available only by prescription through the National Health Service (NHS) or private practitioners. The NHS uses cost-effectiveness assessments by the National Institute for Health and Care Excellence (NICE) to determine which peptide drugs are funded. This has practical consequences: semaglutide for weight loss (Wegovy) received NICE approval with restrictions (BMI thresholds, specialist prescribing), limiting its availability compared to the US market where private insurance and cash-pay models allow broader access.

Compounding in the UK is governed by the "specials" regime under the Human Medicines Regulations 2012, which permits unlicensed medicines to be manufactured on a named-patient basis against a prescription. Peptide compounding is more restricted than in the US, with no equivalent to the 503B outsourcing facility framework.

Australia: TGA

The Therapeutic Goods Administration (TGA) regulates peptide drugs through a risk-based tiered system. Medicines are either "registered" (requiring full evaluation of safety, quality, and efficacy) or "listed" (lower risk, evaluated primarily for quality and safety). Most therapeutic peptides require registration.

Australia's most distinctive regulatory feature for peptides is the "comparable overseas regulator" pathway. The TGA recognizes that its relatively small market makes independent evaluation of every drug product inefficient. If a peptide has been approved by a "comparable" regulator (the FDA, EMA, Health Canada, or others), the TGA can leverage that assessment to expedite its own review. This can reduce evaluation from 12-18 months to as little as 4-6 months.

Australian access challenges

Despite regulatory mechanisms for fast-tracking approvals, Australia faces unique access challenges for peptide drugs. Geographic remoteness increases supply chain costs. The Pharmaceutical Benefits Scheme (PBS) determines government subsidy eligibility, and drugs not on the PBS can be prohibitively expensive. Semaglutide was available in Australia for type 2 diabetes years before it received PBS listing for weight management, creating a two-tier access system based on indication.

The TGA's approach to peptide compounding is restrictive. Compounding pharmacies in Australia can prepare patient-specific prescriptions but face stricter quality standards than many US 503A pharmacies. The direct-to-consumer compounded peptide market that has developed in the United States does not have an equivalent in Australia due to prescribing and dispensing regulations.

Personal importation

Australia's Personal Importation Scheme allows individuals to import up to a 3-month supply of medications for personal use, subject to conditions. This provision has been used to import peptides not yet approved or PBS-listed in Australia, though the TGA can restrict specific substances. The scheme requires a valid prescription in most cases and prohibits importation of certain high-risk or controlled substances.

ICH Harmonization: The Common Ground

The International Council for Harmonisation (ICH) develops consensus guidelines that the FDA, EMA, MHRA, and TGA all adopt, creating a foundation of shared standards despite jurisdictional differences. Key ICH guidelines relevant to peptide drugs include:

• ICH Q6B: specifications for biotechnological and biological products
• ICH Q5C: stability testing of biotechnological/biological products
• ICH Q3A/Q3B: impurity testing (adapted for peptide-specific impurities)
• ICH S6(R1): preclinical safety evaluation for biotechnology-derived pharmaceuticals

These shared standards mean that a peptide manufacturer conducting clinical trials simultaneously in the US, EU, UK, and Australia can use a single analytical and manufacturing framework acceptable to all four regulators. This harmonization has been essential for the global development of GLP-1 agonists, which were tested in multinational trials and approved sequentially across jurisdictions.

What the Differences Mean in Practice

The practical impact of regulatory variation depends on context. For a pharmaceutical company developing a new peptide drug, the key difference is approval pathway speed and data requirements. MHRA's ILAP and TGA's comparable regulator pathway can provide faster access than the FDA or EMA centralized procedure for follow-on jurisdictions. For patients, the differences manifest as access timelines (a drug may be available in the US for 1-2 years before reaching Australia or the EU), cost (NHS vs. PBS vs. US insurance), and compounding availability (broadly accessible in the US, highly restricted in Australia and the UK). For researchers, the differences affect which peptides are legally obtainable for clinical investigation and under what conditions.

The Bottom Line

Peptide drug regulation varies across the four major jurisdictions in approval pathways, compounding frameworks, and patient access models. The FDA has the largest approved peptide portfolio and the most permissive compounding framework (503A/503B), but is now tightening enforcement. The EMA is establishing peptide-specific quality guidelines. The MHRA offers the fastest innovative pathway (ILAP) for new peptides. The TGA can leverage overseas approvals for expedited review but limits compounding and access. ICH harmonization provides shared analytical and quality standards, but the practical experience of peptide regulation remains highly dependent on jurisdiction.

Frequently Asked Questions

How does the FDA regulate peptide drugs?

The FDA regulates peptides of 40 or fewer amino acids as small-molecule drugs through the NDA/ANDA pathway, and larger peptides through the Biologics License Application (BLA) pathway. Over 130 peptide products have FDA approval as of 2025. Compounding pharmacies can prepare peptides under 503A (patient-specific) or 503B (outsourcing facility) provisions, though the FDA significantly tightened compounding rules in 2025 and sent 50+ warning letters to GLP-1 compounders.

Can you import peptides into Australia legally?

Australia's Personal Importation Scheme allows individuals to import up to a 3-month supply of medications for personal use, typically requiring a valid prescription. The TGA can restrict specific substances. Compounded peptides face stricter regulations in Australia than in the United States, and the direct-to-consumer compounded peptide market common in the US does not exist in Australia due to prescribing and dispensing rules.

How does UK peptide regulation differ from the EU after Brexit?

Since Brexit, the MHRA operates independently from the EMA. Peptide drugs previously approved through the EMA were grandfathered into UK marketing authorizations, but new peptides require separate MHRA approval. The MHRA introduced the Innovative Licensing and Access Pathway (ILAP) in 2021, which enables earlier regulatory engagement and rolling review. The MHRA can also leverage FDA or EMA approvals through its International Recognition Procedure.

Are compounded peptides the same quality as branded drugs?

Not necessarily. Hach et al. (Pharmaceutical Research, 2024) compared follow-on GLP-1 polypeptide drugs to branded formulations and found measurable differences in purity, impurity profiles, and stability. Liu et al. (2025) noted that compounded semaglutide often uses the sodium salt form rather than the base form in branded products, creating pharmacokinetic differences. These quality variations are a key reason for increased FDA enforcement.

Which country approves peptide drugs fastest?

It depends on whether the peptide is first-in-class or a follow-on approval. For first-in-class peptides, the FDA and EMA typically process approvals in 10-12 months. For peptides already approved in another jurisdiction, the UK's MHRA (via ILAP and International Recognition) and Australia's TGA (via the comparable overseas regulator pathway) can approve in as little as 4-6 months by leveraging existing regulatory assessments.

What is ICH harmonization for peptide drugs?

The International Council for Harmonisation (ICH) develops consensus guidelines adopted by the FDA, EMA, MHRA, TGA, and other regulators. Key peptide-relevant guidelines include ICH Q6B (specifications), Q5C (stability testing), Q3A/Q3B (impurities), and S6(R1) (preclinical safety). These shared standards allow multinational peptide clinical trials and manufacturing to use a single framework acceptable across all major jurisdictions.